SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?


To: Douglas Babbin who wrote (860)12/4/1998 3:06:00 PM
From: FNS  Respond to of 965
 
Re; <I'm am very curious why IMNX is going up so much. Is their EMBREL a better product for rheumatiod arthritis than CNTO's Remicade?>

ENBREL's first major product approval...CNTO has yet to file for RA approval...statistically, I can't quote the study results comparison but I suspect REMICADE will be looked at very closely by FDA for serious side effects. IMNX is thus winning the ball game. (IMHO)

FNS